These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 34174153

  • 1. Cytomegalovirus transmission in mismatched solid organ transplant recipients: Are factors other than anti-viral prophylaxis at play?
    Hernandez C, Mabilangan C, Burton C, Doucette K, Preiksaitis J.
    Am J Transplant; 2021 Dec; 21(12):3958-3970. PubMed ID: 34174153
    [Abstract] [Full Text] [Related]

  • 2. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ, Razonable RR.
    Drugs; 2010 May 28; 70(8):965-81. PubMed ID: 20481654
    [Abstract] [Full Text] [Related]

  • 3. Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs.
    Mabilangan C, Burton C, Nahirniak S, O'Brien S, Preiksaitis J.
    Am J Transplant; 2020 Dec 28; 20(12):3509-3519. PubMed ID: 32428296
    [Abstract] [Full Text] [Related]

  • 4. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, Mao C, Garro R, Yildirim I.
    Pediatr Transplant; 2023 Jun 28; 27(4):e14493. PubMed ID: 36945819
    [Abstract] [Full Text] [Related]

  • 5. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
    Belga S, Hernandez C, Kabbani D, Cervera C.
    Transpl Infect Dis; 2024 Apr 28; 26(2):e14227. PubMed ID: 38180285
    [Abstract] [Full Text] [Related]

  • 6. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S, Faulds D.
    Drugs; 1998 Jul 28; 56(1):115-46. PubMed ID: 9664203
    [Abstract] [Full Text] [Related]

  • 7. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb 28; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 8. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.
    J Infect Dis; 2001 Dec 01; 184(11):1461-4. PubMed ID: 11709790
    [Abstract] [Full Text] [Related]

  • 9. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.
    Transpl Infect Dis; 2015 Oct 01; 17(5):637-46. PubMed ID: 26134282
    [Abstract] [Full Text] [Related]

  • 10. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 01; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus surveillance after antiviral prophylaxis in CMV mismatched transplant patients: Does recurrent cytomegalovirus DNAemia impact patient survival?
    Fernández-García OA, Hernandez C, Robbins M, Kabbani D, Doucette K, Cervera C.
    Transpl Infect Dis; 2024 Aug 01; 26(4):e14292. PubMed ID: 38728099
    [Abstract] [Full Text] [Related]

  • 12. Donor Cytomegalovirus Transmission Patterns in Solid Organ Transplant Recipients With Primary Infection.
    Hasing ME, Pang XL, Mabilangan C, Preiksaitis JK.
    J Infect Dis; 2021 Mar 03; 223(5):827-837. PubMed ID: 32706857
    [Abstract] [Full Text] [Related]

  • 13. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 03; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 14. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
    Geris JM, Spector LG, Pfeiffer RM, Limaye AP, Yu KJ, Engels EA.
    Cancer; 2022 Nov 15; 128(22):3985-3994. PubMed ID: 36126024
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun 15; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 16. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar 15; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR.
    World J Gastroenterol; 2008 Aug 21; 14(31):4849-60. PubMed ID: 18756591
    [Abstract] [Full Text] [Related]

  • 18. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison MG.
    Transpl Infect Dis; 2016 Jun 21; 18(3):390-5. PubMed ID: 27037651
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 20. Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive/recipient seronegative (D+R-) liver transplant recipients (LTxR).
    Doss KM, Kling CE, Heldman MR, Singh N, Wagener M, Rakita RM, Fisher CE, Limaye AP.
    Transpl Infect Dis; 2023 Apr 16; 25(2):e14015. PubMed ID: 36734631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.